Immuneering reports smaller-than-expected Q3 net loss

Reuters11-13

Immuneering reports smaller-than-expected Q3 net loss

Overview

Immuneering Q3 net loss of $15 mln beats analyst expectations
Company raised $225 mln, extending cash runway into 2029
Reported 86% overall survival at 9 months in pancreatic cancer trial

Outlook

Company expects cash runway to fund operations into 2029
Immuneering to report updated survival data in 1H 2026

Result Drivers

FINANCING SUCCESS - Raised $225 mln, including $25 mln from Sanofi, extending cash runway into 2029
R&D expenses for the third quarter of 2025 were $10.9 million, compared with $11.3 million for the third quarter of 2024
PATIENT RESPONSES - Case studies show complete response and curative intent treatment in pancreatic cancer patients

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 EPS	Beat	-$0.38	-$0.39 (5 Analysts)
Q3 Net Income	Beat	-$15 mln	-$16.73 mln (4 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Immuneering Corp is $13.50, about 50.1% above its November 11 closing price of $6.74

Press Release: ID:nGNX80G5Ql

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2583979583?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-13 05:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2583979583","market":"nz","top_or_hot":-1,"title":"Immuneering reports smaller-than-expected Q3 net loss","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Immuneering reports smaller-than-expected Q3 net loss </title></head><body><p><span>Overview</span></p><ul><li><p>Immuneering Q3 net loss of $15 mln beats analyst expectations</p></li><li><p>Company raised $225 mln, extending cash runway into 2029</p></li><li><p>Reported 86% overall survival at 9 months in pancreatic cancer trial</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company expects cash runway to fund operations into 2029</p></li><li><p>Immuneering to report updated survival data in 1H 2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>FINANCING SUCCESS - Raised $225 mln, including $25 mln from <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a>, extending cash runway into 2029</p></li><li><p> R&amp;D expenses for the third quarter of 2025 were $10.9 million, compared with $11.3 million for the third quarter of 2024</p></li><li><p>PATIENT RESPONSES - Case studies show complete response and curative intent treatment in pancreatic cancer patients</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 EPS</p></td><td><p>Beat</p></td><td><p>-$0.38</p></td><td><p>-$0.39 (5 Analysts)</p></td></tr><tr><td><p>Q3 Net Income</p></td><td><p>Beat</p></td><td><p>-$15 mln</p></td><td><p>-$16.73 mln (4 Analysts)</p></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 6 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for <a href=\"https://laohu8.com/S/IMRX\">Immuneering Corp</a> is $13.50, about 50.1% above its November 11 closing price of $6.74</p></li></ul><p>Press Release: <span>ID:nGNX80G5Ql</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Immuneering reports smaller-than-expected Q3 net loss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImmuneering reports smaller-than-expected Q3 net loss\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-13 05:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Immuneering reports smaller-than-expected Q3 net loss </title></head><body><p><span>Overview</span></p><ul><li><p>Immuneering Q3 net loss of $15 mln beats analyst expectations</p></li><li><p>Company raised $225 mln, extending cash runway into 2029</p></li><li><p>Reported 86% overall survival at 9 months in pancreatic cancer trial</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company expects cash runway to fund operations into 2029</p></li><li><p>Immuneering to report updated survival data in 1H 2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>FINANCING SUCCESS - Raised $225 mln, including $25 mln from <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a>, extending cash runway into 2029</p></li><li><p> R&amp;D expenses for the third quarter of 2025 were $10.9 million, compared with $11.3 million for the third quarter of 2024</p></li><li><p>PATIENT RESPONSES - Case studies show complete response and curative intent treatment in pancreatic cancer patients</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 EPS</p></td><td><p>Beat</p></td><td><p>-$0.38</p></td><td><p>-$0.39 (5 Analysts)</p></td></tr><tr><td><p>Q3 Net Income</p></td><td><p>Beat</p></td><td><p>-$15 mln</p></td><td><p>-$16.73 mln (4 Analysts)</p></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 6 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for <a href=\"https://laohu8.com/S/IMRX\">Immuneering Corp</a> is $13.50, about 50.1% above its November 11 closing price of $6.74</p></li></ul><p>Press Release: <span>ID:nGNX80G5Ql</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nL1N3WO13K:1","article_id":"2583979583","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2583979583","pubTimestamp":1762982675,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Immuneering reports smaller-than-expected Q3 net lossOverviewImmuneering Q3 net loss of $15 mln beats analyst expectationsCompany raised $225 mln, extending cash runway into 2029Reported 86% overall s","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","IMRX":"Immuneering Corp","BK4563":"昨日强势股","BK4539":"次新股"},"translate_title":"Immuneering报告第三季度净亏损小于预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IMRX":0.9},"content_text":"Immuneering reports smaller-than-expected Q3 net loss OverviewImmuneering Q3 net loss of $15 mln beats analyst expectationsCompany raised $225 mln, extending cash runway into 2029Reported 86% overall survival at 9 months in pancreatic cancer trialOutlookCompany expects cash runway to fund operations into 2029Immuneering to report updated survival data in 1H 2026Result DriversFINANCING SUCCESS - Raised $225 mln, including $25 mln from Sanofi, extending cash runway into 2029 R&D expenses for the third quarter of 2025 were $10.9 million, compared with $11.3 million for the third quarter of 2024PATIENT RESPONSES - Case studies show complete response and curative intent treatment in pancreatic cancer patientsKey DetailsMetricBeat/MissActualConsensus EstimateQ3 EPSBeat-$0.38-$0.39 (5 Analysts)Q3 Net IncomeBeat-$15 mln-$16.73 mln (4 Analysts)Analyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 6 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy\"Wall Street's median 12-month price target for Immuneering Corp is $13.50, about 50.1% above its November 11 closing price of $6.74Press Release: ID:nGNX80G5QlFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2583979583","isCrawlerRequest":true}